We studied micronucleus frequencies in former German uranium miners of the Wismut SDAG (Sowjetisch-Deutsche Aktiengesellschaft). Various other groups were analyzed for comparison (individuals with lung tumors or lung fibrosis, controls). We had shown previously that micronucleus frequencies were not different among the various groups. Differences were observed, however, when centromere-positive and -negative micronuclei were distinguished. In the analyses presented here, we looked for the effects of smoking habits, alcohol consumption, vitamin uptake, chronic diseases, allergies, doing sports, γ-GT (gamma-glutamyltranspeptidase), lymphocyte numbers, CEA (carcinoembryonic antigen), X-ray diagnostics, computer tomographies, and scintigraphies. With the exception of more than one scintigraphy carried out during the last four months before micronucleus analysis, none of the factors mentioned above significantly affected micronucleus numbers. One result deserves specific attention: individuals with low percentages of binucleated lymphocytes after in vitro cytochalasin B exposure showed higher micronucleus frequencies than those individuals with high percentages of binucleated cells. The same result was obtained for various other populations that we monitored in the past.   

1.
Bonassi SA, Abbondandolo A, Camurri L, Dalpra L, DeFerrari M, Degrassi F, Forni A, Lamberti L, Lando C, Padovani P, Sbrana I, Vecchio D, Puntoni R: Are chromosome aberrations in circulating lymphocytes predictive for future cancer onset in humans? Cancer Genet Cytogenet 79:133–135 (1995).
2.
Fenech M, Morley AA: Measurement of micronuclei in lymphocytes. Mutat Res 147:29–36 (1985).
3.
Gantenberg H-W, Wuttke K, Streffer C, Müller W-U: Micronuclei in human lymphocytes irradiated in vitro or in vivo. Radiat Res 128:276–281 (1991).
4.
Hagmar L, Brogger A, Hansteen IL, Heim S, Hogstedt B, Knudsen L, Lambert B, Linnainmaa K, Mitelman F, Nordenson I, Reuterwall L, Salomaa C, Skerfving S, Sorsa M: Cancer risk in humans predicted by increased level of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 54:2919–2922 (1994).
5.
Hagmar L, Bonassi S, Stromberg U, Brogger A, Knudsen LE, Norppa H, Reuterwall C: Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res 58:4117–4121 (1998).
6.
Hoffmann GR, Sayer AM, Littlefield LG: Higher frequency of chromosome aberrations in late-arising first-division metaphases than in early-arising metaphases after exposure of human lymphocytes to X-rays in G0. Int J Radiat Biol 78:765–772 (2002).
7.
Jacobi W, Lehmann F, Renner H-J: Anleitung und Tabellen zur Berechnung der Verursachungswahrscheinlichkeit extrapulmonaler Krebserkrankungen durch die berufliche Strahlenexposition von Beschäftigten der ehemaligen WISMUT AG (BG Feinmechanik und Elektrotechnik, Köln 1997).
8.
Kryscio A, Ulrich Muller WU, Wojcik A, Kotschy N, Grobelny S, Streffer C: A cytogenetic analysis of the long-term effect of uranium mining on peripheral lymphocytes using the micronucleus-centromere assay. Int J Radiat Biol 77:1087–1093 (2001).
9.
Müller W-U, Streffer C: Micronucleus assays. Adv Mutag Res 5:1–133 (1994).
10.
Müller W-U, Streffer C, Wuttke K: Micronucleus determination as a means to assess radiation exposure. Stem Cells 13:199–206 (1995).
11.
Popp W, Plappert U, Muller WU, Rehn B, Schneider J, Braun A, Bauer PC, Vahrenholz C, Presek P, Brauksiepe A, Enderle G, Wust T, Bruch J, Fliedner TM, Konietzko N, Streffer C, Woitowitz HJ, Norpoth K: Biomarkers of genetic damage and inflammation in blood and bronchoalveolar lavage fluid among former German uranium miners: a pilot study. Radiat environ Biophys 39:275–282 (2000).
12.
Streffer C, Müller W-U, Kryscio A, Böcker W: Micronuclei – biological indicator for retrospective dosimetry after exposure to ionizing radiation. Mutat Res 404:101–105 (1998).
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.